tedizolid

tedizolid. It is a second-generation oxazolidinone-class antibiotic developed for the treatment of acute bacterial skin and skin structure infections. Approved by the Food and Drug Administration in 2014 and the European Medicines Agency in 2015, it is marketed under the brand name Sivextro. Its development addressed limitations of earlier agents in its class, offering a potent therapeutic option against resistant Gram-positive bacteria.

Medical uses

Tedizolid is indicated for the treatment of adults with acute bacterial skin and skin structure infections caused by susceptible isolates of designated Gram-positive bacteria. This includes infections due to Staphylococcus aureus, both methicillin-susceptible and methicillin-resistant strains, as well as various Streptococcus species and Enterococcus faecalis. Clinical trials, such as the ESTABLISH program, demonstrated its non-inferiority to linezolid in treating these conditions. Its utility is primarily in combating pathogens resistant to other antimicrobial agents, providing a critical option in the setting of increasing antimicrobial resistance.

Adverse effects

The most common adverse reactions observed in clinical studies include nausea, headache, diarrhea, vomiting, and dizziness. Compared to linezolid, it appears to have a lower potential for causing hematological side effects such as thrombocytopenia, which is a significant concern with prolonged use of the older oxazolidinone. Cases of peripheral and optic neuropathy have been reported with the class and are potential risks. As with all antibiotics, use may result in Clostridioides difficile-associated diarrhea.

Pharmacology

Tedizolid exerts its antibacterial effect by binding to the 50S subunit of the bacterial ribosome, inhibiting the initiation phase of protein synthesis. This mechanism is similar to that of other oxazolidinones but with enhanced binding affinity. It demonstrates potent in vitro activity against a range of Gram-positive pathogens, including those resistant to vancomycin and daptomycin. The drug is administered once daily, either intravenously or orally, with high oral bioavailability allowing for seamless transition between routes.

Chemistry

Tedizolid phosphate is a prodrug that is rapidly converted by phosphatases in the blood to the biologically active moiety, tedizolid. The active compound is a synthetic oxazolidinone derivative characterized by the presence of both a triazole and a tetrazole ring system, which contribute to its potent binding to the ribosomal target and stability against certain resistance mechanisms. Its chemical structure is distinct from linezolid, conferring improved activity against some linezolid-resistant strains due to mutations in the ribosomal RNA.

History

The development of tedizolid was spearheaded by Cubist Pharmaceuticals, following research into next-generation oxazolidinones. It was designed to overcome the limitations of linezolid, the first drug in its class approved by the Food and Drug Administration. After successful Phase III clinical trials, it received approval from the FDA in June 2014. Subsequent regulatory approvals were granted by the European Commission and other health authorities worldwide, cementing its role in the antimicrobial arsenal.

Society and culture

Marketed under the trade name Sivextro, tedizolid is recognized as an important advancement in combating resistant infections. Its development and pricing have been subjects of discussion within the context of the global need for new antibiotics. The drug is often cited in medical literature and guidelines from bodies like the Infectious Diseases Society of America as a treatment option for complex skin infections. Its role is particularly highlighted in the ongoing battle against methicillin-resistant Staphylococcus aureus in both hospital and community settings. Category:Antibiotics